HIF-1α Discovery, Function, and the 2019 Nobel Prize

Discovery

Hypoxia-inducible factor (HIF) was first identified in the early 1990s as a transcription factor that mediates cellular responses to low oxygen levels (hypoxia), below 21% atmospheric oxygen. Its discovery came from studies investigating how cells adapt to hypoxic conditions at 5% oxygen or less, particularly focusing on erythropoietin (EPO) gene regulation. Gregg Semenza and colleagues demonstrated that hypoxia stimulates the expression of EPO in a HIF-dependent manner, which led to the identification of HIF as a key regulator of oxygen homeostasis. HIF was found to be a heterodimer composed of two subunits: HIF-1α and HIF-1β, also known as aryl hydrocarbon nuclear translocator (ARNT). While the HIF-1β subunit is constitutively expressed, HIF-1α levels are tightly controlled by oxygen availability, making it the primary sensor and effector of the hypoxic response.

Functions

HIF functions as a master regulator of gene expression in response to hypoxia. Under normoxic (atmospheric) conditions, HIF-1α is hydroxylated on specific proline residues by prolyl hydroxylase domain-containing enzymes (PHDs), which mark it for recognition and ubiquitination by the von Hippel-Lindau (VHL) E3 ubiquitin ligase complex, leading to its proteasomal degradation. This hydroxylation process requires oxygen as a cofactor, thus serving as a direct oxygen-sensing mechanism. In hypoxia, the activity of PHDs is inhibited due to reduced oxygen availability, resulting in the stabilization and accumulation of HIF-1α. Once stabilized, HIF-1α translocates to the nucleus, where it dimerizes with HIF-1β, to form an active transcriptional complex that binds to hypoxia-responsive elements (HREs) in the promoters of target genes.

The HIF pathway controls the expression of numerous genes involved in critical adaptive responses, including angiogenesis, erythropoiesis, glycolysis, and cell survival. HIF regulates enzymes involved in anaerobic glycolysis, thereby enabling cells to generate ATP in the absence of sufficient oxygen. Additionally, HIF influences iron metabolism, cell proliferation, and apoptosis, highlighting its role in coordinating a broad spectrum of cellular processes in response to oxygen deprivation.

In low oxygen environments, HIF plays a crucial role in endothelial cells by promoting angiogenesis, the formation of new blood vessels. Under hypoxic conditions, HIF induces the expression of vascular endothelial growth factor (VEGF), a key signaling protein that stimulates endothelial cells to proliferate and migrate, forming new capillaries to supply oxygen-deprived tissues. This response is particularly important in wound healing and tissue repair, where restoring oxygen supply is essential for recovery. In tumors, cancer cells exploit this mechanism to support their growth in hypoxic regions by upregulating HIF-dependent angiogenic pathways, leading to the development of a more extensive blood vessel network.

In skeletal muscle cells, HIF regulates metabolic adaptations to sustain energy production during low oxygen availability. Hypoxia drives a shift from aerobic respiration to anaerobic glycolysis through HIF-mediated upregulation of glycolytic enzymes and the glucose transporter GLUT1, which increases glucose uptake. This shift allows skeletal muscle cells to generate ATP in the absence of sufficient oxygen, albeit less efficiently, helping maintain energy homeostasis during periods of intense physical activity or conditions like ischemia, where blood flow is restricted.

In the immune system, HIF influences the function and survival of macrophages and other immune cells in hypoxic environments, such as inflamed tissues or tumors. HIF activation enhances the ability of macrophages to adapt to low oxygen by upregulating genes involved in glycolysis, which supports their energy demands under anaerobic conditions. Additionally, HIF promotes the expression of pro inflammatory cytokines and enzymes like inducible nitric oxide synthase (iNOS), which contribute to the immune response and pathogen defense. This regulation is critical in sites of chronic inflammation or infection, where hypoxia is a common feature.

Oxygen-Independent Regulation

Even in normoxia, growth factors, cytokines, and other signaling pathways can regulate HIF-1α. For instance, growth factors like insulin and IGF-1 can stabilize HIF-1α through the PI3K/AKT/mTOR pathway, enhancing its synthesis and activity even under non-hypoxic conditions. Reactive oxygen species (ROS) and nitric oxide (NO) can also influence HIF-1α stabilization by modulating PHD activity. HIF-1 mRNA can also be affected by microRNAs (miRNAs) that degrade HIF mRNA and long non-coding RNAs (lncRNAs) that promote the function of HIF-1.

Post-Translational Regulation

The regulation of HIF activity is further modulated by other post-translational modifications, such as acetylation, methylation, sumoylation, S-nitrosylation, and phosphorylation, which can affect its stability, transcriptional activity, and interactions with co-factors. HIF signaling is also subject to feedback regulation through the induction of negative regulators like factor inhibiting HIF (FIH), which hydroxylates an asparagine residue on HIF-1α, preventing its interaction with coactivators. These regulatory layers fine tune the HIF response, ensuring that gene expression is dynamically adjusted according to the degree and duration of hypoxia.

Pathogenesis

The significance of HIF extends beyond normal physiology, as dysregulation of the HIF pathway is implicated in various pathologies, including cancer, ischemic diseases, and chronic kidney disease. Tumors often exploit HIF to promote a microenvironment conducive to growth and survival under hypoxic conditions by upregulating angiogenesis, metabolic reprogramming, and resistance to cell death. As such, the HIF pathway has emerged as a therapeutic target, with efforts directed towards developing inhibitors of HIF or its downstream effectors to counteract disease progression.

Nobel Prize

The Nobel Prize in Physiology or Medicine 2019 was awarded jointly to William G. Kaelin Jr., Sir Peter J. Ratcliffe, and Gregg L. Semenza for their groundbreaking discoveries on how cells sense and adapt to oxygen availability. Their research elucidated the molecular mechanisms underlying the cellular response to varying oxygen levels, particularly through the identification and characterization of hypoxia-inducible factor (HIF). Semenza’s work focused on the role of HIF in regulating the expression of the EPO gene in response to hypoxia, while Ratcliffe and Kaelin contributed to uncovering the oxygen-dependent regulation of HIF by the VHL E3 ligase protein, and the role of prolyl hydroxylation in HIF stability.

Kaelin’s research on von Hippel-Lindau disease, a genetic disorder associated with a predisposition to certain cancers, led to the discovery that the VHL protein is essential for HIF-1α degradation under normoxic conditions. Concurrently, Ratcliffe and his team demonstrated that prolyl hydroxylation serves as the oxygen-sensing step, marking HIF-1α for VHL-mediated degradation. These complementary findings established the molecular link between oxygen sensing and the regulation of HIF, significantly advancing the understanding of cellular adaptation to hypoxia.

The recognition of these discoveries with the Nobel Prize highlighted the fundamental importance of oxygen sensing in physiology and its implications for human health. HIF-1 has been identified as a transcription factor for over 1000 targets and as of 2024, has been cited as a key term in over 26,000 research articles, according to PubMed, underscoring the broad importance of this key molecule in biology. The mechanisms uncovered have not only provided insights into normal physiological processes like metabolism, development, immunity, and wound healing but also shed light on disease pathogenesis, particularly in cancer, cardiovascular, and ischemic diseases. The Nobel Prize underscored the potential for therapeutic interventions targeting the HIF pathway to treat conditions associated with abnormal oxygen sensing.

Learn more about how Embrient’s Modular Incubator Chamber
supports HIF-1 and hypoxia research

Featured Content

Join our eNewsletter

Stay up-to-date with our latest technical notes, announcements, and new products.